Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135581 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAMAPTNR3C1PGR | |
| SCHEMBL29665700 | 0.78 | TUBB1 (0.43) | SMN1; SMN2LMNAMEP1BALDH1A1HTT | |
| SCHEMBL7535556 | 0.78 | TUBB1 (0.43) | SMN1; SMN2LMNAMEP1BALDH1A1HTT | |
| SCHEMBL22909472 | 0.76 | CA1 (0.51) | CA1CA2CA9ALDH1A1HTT | |
| SCHEMBL29671244 | 0.76 | CA1 (0.51) | CA1CA2CA9ALDH1A1HTT | |
| Batabulin SCHEMBL29373304 | 0.75 | LMNA (0.54) | CA1CA2SMN1; SMN2LMNAMAPT | |
| Batabulin SCHEMBL18845 | 0.75 | LMNA (0.54) | CA1CA2SMN1; SMN2LMNAMAPT | |
| SCHEMBL16135696 | 0.75 | KDM1A (0.42) | SMN1; SMN2LMNAMAPTNR3C1PGR | |
| Batabulin SCHEMBL6089508 | 0.74 | LMNA (0.53) | CA1CA2SMN1; SMN2LMNAMAPT | |
| Batabulin SCHEMBL6086887 | 0.74 | LMNA (0.53) | CA1CA2SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2020-09-03 | — | — | US | disclosed |
| WO-2019056120-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKI67, PKD1, ETV6 | CA1 498/4885CA2 892/4885SMN1; SMN2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.